Preparation method and application of anti-tumor clam peptide

Through the preparation of Red Island clams, the gap in anti-tumor and immune regulation functions of colorectal cancer was solved, and clam peptide powder with anti-tumor and enhanced immune function was prepared, which significantly inhibited tumor cell growth and metastasis, relieved cancer symptoms, and opened up clam peptides New uses in the fields of anti-tumor and immunomodulation.

CN118910197APending Publication Date: 2024-11-08颐海产业控股有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411018811.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is a lack of application of anti-tumor active clam peptides for direct inhibition of colorectal cancer and immune enhancement in the prior art, especially in anti-tumor and its immune regulatory functions.

Method used

Clam peptides were prepared by Red Island Clams (Philippine clams). Through enzymatic decomposition, centrifugation, purification and drying, clam peptide powder with anti-tumor and immune enhancement functions was prepared for anti-tumor drugs and immunomodulatory drugs. Development.

Benefits of technology

Clam peptide significantly inhibits tumor cell growth and metastasis, promotes cell apoptosis, regulates gene expression, effectively alleviates the symptoms of colorectal cancer, reduces the expression of tumor-related factors, significantly inhibits tumor spread and growth, and opens up the fields of anti-tumor and immune regulation of clam peptides. new use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910197A_ABST
    Figure CN118910197A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of anti-tumor clam peptide, and belongs to the technical field of biological medicine. The invention discloses a preparation method of an anti-tumor clam peptide. The clam peptide is prepared by adopting the methods of enzymolysis, centrifugation, purification and drying. The clam peptide prepared by the invention is not limited to colorectal cancer tumor inhibition, adjuvant therapy and immunity regulation, but also suitable for inhibition and adjuvant therapy of other tumors and improvement of organism immunity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and more specifically to a preparation method and application of an anti-tumor clam peptide. Background Art

[0002] Cancer is not just the result of a series of biological events, but a complex, multi-factor driven disease process. It involves the interaction of multiple aspects such as tumor cells, tumor microenvironment (TME), host metabolism and immune system. These factors work together to affect the occurrence, development and treatment response of cancer. TME is a key site for the interaction between immune cells and cancer cells, and is a fertile soil for tumor survival, development and immune evasion. The immune response is the body's natural barrier against tumors, and an imbalance in immune effects is the main cause of tumor occurrence and development. The immune system plays a dual role in cancer: on the one hand, it is a guardian against tumor cells, and on the other hand, cancer cells can manipulate the immune system to promote their own survival.

[0003] Colorectal cancer is a common malignant tumor in clinical practice. It is prone to occur in middle-aged and elderly people, and the incidence rate is increasing year by year. Due to the lack of specific symptoms in the early stages of colorectal cancer, the early diagnosis rate is low. Most patients have already developed to the middle and late stages when diagnosed, which increases the difficulty of radical surgery, affects the prognosis of the disease, and seriously affects the patient's life expectancy. Surgery is currently the main measure for the treatment of colorectal cancer. It is suitable for early and middle-stage patients. After surgery, it is combined with comprehensive treatments such as radiotherapy, chemotherapy, targeted therapy, immunotherapy, and traditional Chinese medicine. However, the surgical effect of late-stage patients is poor, and it has a greater impact on the body's immune function, leading to obvious adverse reactions in the digestive system and immune system, which seriously affects the quality of life of colorectal cancer patients.

[0004] Macrophages are highly plastic natural immune cells and a major component of TME. They are the main reason why the body maintains its own immune balance for a long time. Studies have shown that food-derived immunoactive peptides can stimulate the immune system to eliminate invaders, repair body damage and improve immunity. The report pointed out that peptides from a variety of food sources have immune enhancement and regulatory effects in vitro and animal experiments. Active peptides obtained from foods such as salmon, clams and eggs mainly increase the phagocytic ability of RAW264.7 macrophages, nitric oxide (nitric oxide, NO) production, nitric oxide synthase (nitric oxide synthase, iNOS) expression, intracellular reactive oxygen species (reactive oxygen species, ROS) generation and cytokine secretion to exert immunomodulatory effects. In addition, compared with drugs, food-derived immunoactive peptides have the advantages of being non-toxic, easier to absorb and less immunogenic.

[0005] The Philippine clam is an important high-quality marine resource with delicious meat, rich nutritional value, high protein and low fat. It contains abundant physiologically active substances such as peptides, polysaccharides, glycosaminoglycans, etc. Studies have shown that clam peptides are small molecule bioactive peptides of marine origin, which are highly safe, easily absorbed, and have multiple biological activities such as antioxidant, anti-inflammatory, antibacterial, and regulation of blood sugar and blood lipids. Marine clam active peptides have become a hot topic of research, but there are few reports on the anti-tumor and immunomodulatory activity of clam peptides.

[0006] After searching, it was found that there are two public patent documents related to this patent application: (1) "A preparation method and application of clam peptides for anti-inflammatory and kidney protection" (CN202110997320.9), which provides an application of clam peptides in drugs for alleviating renal damage caused by hypertension. It is a functional application of clam peptides in the field of anti-inflammatory and kidney protection. (2) "Angiotensin converting enzyme inhibitory peptides and their preparation method and application" (CN201310212991.5) provides an application of clam peptides in inhibiting angiotensin converting enzyme and their preparation method. It is a functional application of clam peptides in the field of lowering blood pressure.

[0007] By comparison, the technical solutions and application fields of the above-mentioned public patent documents are fundamentally different from those of this patent, and there is currently no application of clam peptides in anti-tumor and immunomodulatory functions, especially no direct inhibitory effect on colorectal tumors in situ and anti-tumor activity that enhances immunity.

[0008] Therefore, providing a preparation method and application of anti-tumor clam peptides is an urgent problem to be solved by those skilled in the art. Summary of the invention

[0009] In view of this, the present invention provides a preparation method and application of an anti-tumor clam peptide, filling the gap in the preparation and application of anti-tumor clam peptides.

[0010] The purpose of the present invention is to prepare clam peptides from Hongdao clam (Philadelphus philippinarum), and use them to inhibit tumor cells and regulate the body's immune function. It can also be further applied to the treatment of other tumors, as well as to assist in enhancing the body's immune regulation ability and cell damage repair.

[0011] In order to achieve the above object, the present invention adopts the following technical solution:

[0012] A method for preparing an anti-tumor clam peptide, the specific steps are as follows:

[0013] (1) The whole meat of Manila clam is used as raw material, washed and homogenized with pure water to obtain a clam meat slurry with a ratio of raw material to pure water of 1:2-3, the pH value thereof is adjusted to 7.8-8.5, the enzymatic hydrolysis temperature is set to 37-38° C., 0.03%-0.05% of trypsin by weight of the raw material is added, and after enzymatic hydrolysis for 3-5 hours, the enzyme is inactivated to obtain an enzymatic hydrolyzate; the enzymatic activity of the trypsin is 2500U;

[0014] (2) centrifuging the enzymatic hydrolysate obtained in step (1), discarding the precipitate, filtering the supernatant through a 10 μm microfiltration membrane-50,000 Da ultrafiltration membrane-400 Da nanofiltration membrane, and intercepting the enzymatic hydrolysate with a molecular weight between 400 Da and 50,000 Da; spray drying to obtain clam peptide (powder), the purity of which reaches 70% or more (in terms of polypeptide content), and the proportion of peptides with a relative molecular mass of less than 5,000 Da reaches 97% or more.

[0015] Furthermore, the enzyme inactivation treatment in step (1) is performed at 80-100° C. for 15-20 min.

[0016] Furthermore, the centrifugation in step (2) is performed at 5000 rpm for 20 min.

[0017] Furthermore, the clam peptide prepared by the preparation method.

[0018] Furthermore, the clam peptide is used in the preparation of anti-tumor drugs.

[0019] Furthermore, the tumor is colorectal cancer.

[0020] Furthermore, the clam peptide is used in the preparation of immunomodulatory drugs.

[0021] Furthermore, the drug is in oral, injectable or external dosage form.

[0022] Using trypsin-membrane coupling technology, a clam peptide powder with excellent color and taste, anti-tumor and immune-enhancing functions, and easy absorption by the human body is produced through enzymatic hydrolysis, centrifugation, purification, drying and other processing technologies. It can be used in the preparation of anti-tumor drugs and products related to tumor treatment with immune-enhancing functions, so as to achieve high-value utilization of clam meat.

[0023] In order to clarify the amino acid sequence of active peptides in clam peptide powder, clam peptide powder (400-50000Da) was dissolved in an appropriate amount of pure water, and two components of 400-5000Da and 5000-50000Da were obtained by ultrafiltration through a 5000Da ultrafiltration membrane: component 1 (400Da-5000Da) and component 2 (5000-50000Da). The two components were collected for Sephadex gel filtration chromatography, and the component with a higher inhibition rate on the proliferation of human colon cancer cells HT-29 was identified by LC-MS / MS for amino acid sequence. By comparing with the protein database, 10 peptide segments were identified: IIVDELK, VFPSRR, ALFLK, ILFIR, VVTAVK, EIAQDFK, RLIGR, LTGMAFR, VFLENVIR, VLDSQKK.

[0024] The clam peptide described in the present invention has good effects in inhibiting tumor cell growth and metastasis, promoting tumor cell apoptosis and inhibiting angiogenesis in a zebrafish tumor transplantation model, and can also upregulate the expression of Bax, IFNG1 and TNF-α genes and downregulate the expression of vegfaa gene.

[0025] The clam peptide described in the present invention exerts good anti-tumor effects and immune regulation effects in mice with colorectal inflammation in situ tumor model. It effectively alleviates the symptoms of colorectal lesions, significantly reduces the content of IL-1β, CEA, LPS, etc., significantly reduces the high expression of COX-2, Ki67 and PCNA caused by tumors, and effectively inhibits the spread and growth of tumors.

[0026] The application of the clam peptide described in the present invention is not limited to colorectal cancer tumor inhibition, adjuvant therapy and immune regulation, but is also applicable to other tumor inhibition and adjuvant therapy and improving body immunity.

[0027] The clam peptides described in the present invention can be used for the preparation of anti-tumor drugs and drugs for improving immunity, and can be in any dosage form permitted by pharmacy, including oral (powder, tablet, capsule, oral liquid, etc.), injection and external dosage forms.

[0028] The clam peptide described in the present invention can be used as a direct anti-tumor therapeutic drug, and a component of related products for enhancing immunity and assisting tumor treatment.

[0029] It can be seen from the above technical solutions that, compared with the prior art, the present invention discloses a preparation method and application of an anti-tumor clam peptide, which has the following beneficial effects:

[0030] (1) The clam peptide of the present invention has been confirmed by experiments to have significant effects of inhibiting tumor cell growth and metastasis, promoting cell apoptosis, and inhibiting angiogenesis. At the same time, it can upregulate the expression of Bax, IFNG1 and TNF-α genes and downregulate the expression of vegfaa gene.

[0031] (2) The clam peptide of the present invention has been proven through experiments to have a good effect in alleviating the symptoms of colorectal cancer, can release numerous anti-tumor factors, effectively inhibit the spread and growth of tumors, and at the same time reduce the high expression of COX-2, Ki67 and PCNA caused by tumors.

[0032] (3) The present invention has opened up new medical and health-care uses for clam peptides, which are highly safe and easily absorbed, and provide a food-derived drug option for patients to fight tumors and regulate immune function. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0034] Figure 1 The attached figure shows the fluorescence intensity of zebrafish tumor cells after being treated with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001;

[0035] Figure 2 The accompanying figure shows the effect of inhibiting tumor growth in zebrafish after being treated with the samples of the present invention;

[0036] Figure 3 The attached figure shows the metastasis distance of zebrafish tumor cells after being treated with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001;

[0037] Figure 4 The accompanying figure shows the efficacy of inhibiting tumor metastasis in zebrafish after being treated with the samples of the present invention;

[0038] Figure 5 The attached figure shows the fluorescence intensity of apoptotic cells in zebrafish after treatment with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001;

[0039] Figure 6 The accompanying figure shows the effect of promoting cell apoptosis in zebrafish after being treated with the samples of the present invention;

[0040] Figure 7The attached figure shows the number of intestinal blood vessel sprouts in zebrafish after being treated with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001;

[0041] Figure 8 The attached figure shows the angiogenesis inhibition effect of zebrafish after being treated with the samples of the present invention;

[0042] Fig. 9 The attached figure shows the relative expression of Bax gene in zebrafish after treatment with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01;

[0043] Fig.10 The attached figure shows the relative expression of IFNG1 gene in zebrafish after treatment with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001;

[0044] Fig.11 The attached figure shows the relative expression of TNF-α gene in zebrafish after treatment with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001;

[0045] Fig.12 The attached figure shows the relative expression of vegfaa gene in zebrafish after treatment with the samples of the present invention; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001;

[0046] Fig.13 The accompanying drawings show the statistical results of the weight of mice and the length of the colon of mice of the present invention; wherein, A: the statistical results of the weight of mice; B: the statistical results of the length of the colon of mice;

[0047] Fig.14 The accompanying figure is HE staining of mouse colon sections of the present invention;

[0048] Fig.15 The attached figure shows the expression levels of inflammatory factors in the serum of mice of the present invention; wherein, A: IL-2; B: IL-10; C: IL-1β; D: TNF-α;

[0049] Fig.16 The attached figure shows the expression levels of CEA and LPS in the serum of mice of the present invention; wherein, A: CEA; B: LPS;

[0050] Fig.17 The attached figure shows the expression levels of CD86, INOS, CD206 and COX-2 in the colon tissue of mice of the present invention; wherein, A: CD86; B: INOS; C: CD206; D: COX-2;

[0051] Fig.18The attached figure shows the expression levels of Ki67 and PCNA in the colon tissue of mice of the present invention; wherein, A: Ki67; B: PCNA. DETAILED DESCRIPTION

[0052] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0053] Example 1

[0054] A method for extracting and purifying anti-tumor clam peptides, taking the whole meat of Manila clam as raw material, and preparing the clam peptides by enzymatic hydrolysis, centrifugation, purification and drying; the specific steps are as follows:

[0055] (1) The whole meat of the Philippine clam was used as the raw material, and after washing, it was homogenized with pure water to obtain a clam meat slurry with a raw material: pure water = 1:2, the pH thereof was adjusted to 8, the enzymatic hydrolysis temperature was set to 37°C, 0.03% of the raw material weight of trypsin (2500U) was added, and after enzymatic hydrolysis for 3h, the enzyme was inactivated (80°C, 20min) to obtain an enzymatic hydrolyzate;

[0056] (2) The enzymatic hydrolysate obtained in step (1) was centrifuged at 5000 rpm for 20 min, the precipitate was discarded, and the supernatant was filtered through a microfiltration membrane (material PP, 10 μm), an ultrafiltration membrane (material PES, 300 KDa) and a nanofiltration membrane (material polyamide composite membrane, 400 Da) to retain the enzymatic hydrolysate with a molecular weight between 400 Da and 300 KDa;

[0057] (3) The enzymatic hydrolysate obtained in step (2) is spray-dried to obtain clam peptides. The yield of clam peptides reaches 4% (based on fresh meat), the purity of clam peptides reaches 70% (based on polypeptide content), and the proportion of peptides with a relative molecular mass of less than 5000Da reaches 97%.

[0058] Test Examples 1-3 were carried out using the clam peptide prepared in Example 1 as a raw material.

[0059] Experimental Example 1 Evaluation of the anti-tumor and immune efficacy of clam peptide samples with different molecular weights in vitro.

[0060] Tumor immunotherapy drugs can promote the polarization of macrophages (RAW264.7), release tumor suppression-related active factors, and then kill tumor cells, thus playing an anti-tumor effect. To explore the effects of different molecular weight clam peptide samples on macrophage morphological changes, phagocytic activity and polarization factor content, determine their tumor suppression efficacy, and screen out active peptides that have a good promoting effect on macrophage polarization.

[0061] RAW264.7 cells (mouse mononuclear macrophage leukemia cells), catalog number TCM13, were purchased from a cell bank. The cells were cultured in a conventional sterile manner (37° C., 5% CO 2 incubator) using DMEM-HG high-glucose medium supplemented with 10% inactivated FBS and 1% double antibody (penicillin-streptomycin).

[0062] In order to study the in vitro anti-tumor and immune effects of clam peptide samples with different molecular weights, the clam peptide powder (400-50000Da) prepared in Example 1 was dissolved in an appropriate amount of pure water, and ultrafiltration was performed through a 3000Da ultrafiltration membrane to obtain component 1 (3000-50000Da) and component 2 (400-3000Da), and component 2 was then passed through a 1000Da ultrafiltration membrane to obtain component 3 (1000-3000Da) and component 4 (400-1000Da). Component 4 had a lower yield and was not selected, and cell experiments were carried out with components 1, 2, and 3.

[0063] Group setting: blank control group, LPS control group, sample group (sample 1 (3000-50000Da), sample 2 (1000-3000Da), sample 3 (400-3000Da), original peptide powder (clam peptide powder, 400-50000Da), concentrations: 250, 500, 1000, 2000μg / mL).

[0064] (1) Cell viability assay (CCK8):

[0065] After cell recovery and culture, 5×10 5 100 μL of cell suspension was inoculated into each well of a 96-well plate, and the final cell concentration was 5×10 4 Each group was set up with 6 replicate wells. After static culture overnight (about 16 hours), different concentrations of drugs were added according to the experimental groups. 100 μL of 1 μg / mL LPS solution was added to the LPS group, 100 μL of each concentration of drug solution was added to the sample group, and 100 μL of complete culture medium was added to the blank control group. The culture was continued for 24 hours. After 24 hours, 10 μL of CCK-8 solution was added to each well. After continuing to culture in the incubator for 2 hours, the absorbance of each well at 450 nm was detected by an enzyme marker (OD values ​​close to 1 are more accurate) and the cell viability was calculated. The results are shown in Table 1.

[0066] Cell viability = [OD(drug added)-OD(blank)] / [OD(control)-OD(blank)]

[0067] OD (drug added): absorbance value of wells with cells, culture medium, CCK-8 solution and drug solution;

[0068] OD (blank): absorbance value of wells with culture medium, CCK-8 solution, and no cells;

[0069] OD (control): absorbance value of the wells with cells, culture medium, CCK-8 solution, and no drug solution.

[0070] Table 1 Effects of different concentrations of each sample on cell viability (CCK8) (n=6)

[0071]

[0072] Note: Compared with the blank control group, *p<0.05, **p<0.01, ***p<0.001.

[0073] (2) Cell phagocytosis of neutral red activity detection:

[0074] After cell recovery and culture, 1×10 6 Take 1 mL of cell suspension and add it to 6-well culture plates containing 1 mL of complete medium. The final cell concentration is 5×10 5 cells / well, cultured overnight (about 16h), then discarded the old solution, added different concentrations of drugs according to the experimental groups, added 2mL of 1μg / mL LPS solution to the LPS group, added 2mL of each concentration of drug solution to the sample group, and added 2mL of complete culture medium to the blank control group, and continued to culture for 24h. After 24h, 200μL of commercial neutral red reagent was added to each well (the volume ratio of culture medium to neutral red reagent was 10:1), shaken evenly, incubated in the incubator for 3h, and then discarded the supernatant; 1mL PBS was added to each well to rinse the cells, and collected in a 15mL centrifuge tube, centrifuged at 3000rpm at room temperature for 10min, and the supernatant was discarded. PBS was blown and mixed to make a single cell suspension, and then diluted and counted under a microscope; cell lysis solution (the same kit as the neutral red reagent, used in conjunction) was added, vortexed and mixed, and placed in a 4℃ refrigerator overnight for lysis. After lysis, the sample was vortexed again and centrifuged at 3000 rpm for 10 min at room temperature. The supernatant was aspirated into a 1.5 mL centrifuge tube and added to a 96-well plate at 100 μL / well after mixing. Three replicate wells were set for each sample. The absorbance value at a wavelength of 540 nm was measured and recorded using an ELISA reader. The results are shown in Table 2.

[0075] Table 2 Effects of different concentrations of each sample on the activity of cell phagocytosis of neutral red OD540nm ( n=3)

[0076]

[0077] Note: Compared with the blank control group, *p<0.05, **p<0.01, ***p<0.001; compared with the LPS control group, #p<0.05, ##p<0.01, ###p<0.001.

[0078] (3) Polarization factor content detection:

[0079] Take the cells in the logarithmic growth phase and discard the old solution, wash the cells twice with PBS, collect the cells, and mix them by pipetting to make a single cell suspension, dilute 10 times, and count them under a microscope to make a 1×10 6 Take 1 mL of cell suspension and add it to 6-well culture plates containing 1 mL of complete medium. The final cell concentration is 5×10 5 Cells / well were placed in a 37°C, 5% CO2 cell culture incubator for overnight culture (about 16 hours), and then the old solution was discarded. Different concentrations of drugs were added according to the experimental groups. 2 mL of 1 μg / mL LPS solution was added to the LPS group, 2 mL of each concentration of drug solution was added to the sample group, and 2 mL of complete culture medium was added to the blank control group. The culture was continued for 24 hours. After 24 hours, centrifugation was performed at 3000 rpm for 20 minutes (4°C), and the supernatant and cells were collected respectively, and cell counting and cell lysis were completed; the secretion levels of TNF-α in the collected supernatant samples and iNOS and CD86 cytokines in the cell lysate samples were detected according to the instructions of the kit. The statistical data results are shown in Tables 3-5.

[0080] Table 3 Effects of different concentrations of each sample on TNF-α content (pg / mL, n=2)

[0081]

[0082] Note: Compared with the blank control group, *p<0.05, **p<0.01, ***p<0.001; compared with the LPS control group, #p<0.05, ##p<0.01, ###p<0.001.

[0083] Table 4 Effects of different concentrations of each sample on iNOS content (ng / mL, n=2)

[0084]

[0085] Note: Compared with the blank control group, *p<0.05, **p<0.01, ***p<0.001; compared with the LPS control group, #p<0.05, ##p<0.01, ###p<0.001.

[0086] Table 5 Effects of different concentrations of each sample on CD86 content (ng / mL, n=2)

[0087]

[0088] Note: Compared with the blank control group, *p<0.05; compared with the LPS control group, #p<0.05, ##p<0.01, ###p<0.001.

[0089] Data are expressed as mean ± standard deviation The data were analyzed using SPSS23.0 statistical software. The data of each group were normally distributed with equal variance. One-way analysis of variance was used, and P < 0.05 was considered statistically significant.

[0090] The results in Tables 1 to 5 indicate that each segmented clam peptide can promote the activity of macrophages in phagocytosing neutral red to a certain extent, and upregulate the expression of CD86, TNF-α and iNOS factors in macrophages; that is, anti-tumor effect is achieved by regulating the polarization of macrophages to M1.

[0091] Experimental Example 2 Evaluation of the anti-tumor efficacy and mechanism of clam peptide samples in zebrafish

[0092] Zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / LCaCO3), and were bred and provided by the Fish Farming Center of Hangzhou Huante Biotechnology Co., Ltd. The experimental animal use license number is: SYXK (Zhejiang) 2022-0004, and the breeding management complies with the requirements of the international AAALAC certification (certification number: 001458).

[0093] Wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 2 days post fertilization (2dpf) were used for the determination of the maximum detectable concentration (MTC) of the samples, the evaluation of the efficacy of inhibiting tumor cell growth, the evaluation of the efficacy of inhibiting tumor cell metastasis, the evaluation of the efficacy of promoting cell apoptosis, and the study of the anti-tumor mechanism of the samples.

[0094] Transgenic zebrafish with green vascular fluorescence Fli-1 strain were bred by natural pair mating. Zebrafish aged 2dpf were used to evaluate the efficacy of the samples in inhibiting angiogenesis.

[0095] Human colon cancer cells (HT-29) were cultured in DMEM medium containing 10% fetal bovine serum and 1% double antibody at 37°C and 5% CO2.

[0096] Grouping: normal control group, model control group, positive control group, sample group. Positive control group: 5-fluorouracil (5-FU, concentration 65, 260 μg / mL). Clam peptide sample group: sample 1 (3000-50000Da), sample 2 (1000-3000Da), sample 3 (400-3000Da); sample 4 (400-50000Da, clam peptide powder), sample 1 combined with 5-FU group (sample 1+5-FU), sample 2 combined with 5-FU group (sample 2+5-FU); sample concentration gradient: 15.6, 31.2, 62.5, 125, 250 μg / mL.

[0097] (1) Experiment on the efficacy of inhibiting tumor cell growth:

[0098] MTC determination: Human colon cancer cells (HT-29) were labeled with CM-DiI and transplanted into the yolk sac of wild-type AB strain zebrafish at 2dpf by microinjection. About 200 cells were transplanted per tail to establish a zebrafish tumor transplantation model. The model zebrafish were cultured at 35°C until 3dpf. At 3dpf, zebrafish with good consistency of transplanted tumor cells were selected under a microscope and randomly assigned to 6-well plates, with 30 tails per well. The samples were given in water (concentrations are shown in Table 6), and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. During the sample processing, the number of zebrafish deaths in each experimental group was counted every day and removed in time. After 48h of treatment at 35°C, the MTC of the sample on the model zebrafish was determined.

[0099] Table 6 Sample anti-tumor efficacy concentration exploration test results (n = 30)

[0100]

[0101]

[0102] Evaluation of the efficacy of inhibiting tumor cell growth: Human colon cancer cells (HT-29) were labeled with CM-DiI and transplanted into the yolk sac of 2dpf wild-type AB strain zebrafish by microinjection. About 200 cells were transplanted per tail to establish a zebrafish tumor transplantation model. The model zebrafish were cultured at 35°C until 3dpf. At 3dpf, zebrafish with good consistency of transplanted tumor cells were selected under a microscope and randomly assigned to 6-well plates, 30 per well. The samples were given water-soluble (concentrations of 31.2, 62.5 and 125μg / mL), positive controls 5-FU (concentrations of 65.0, 260μg / mL), and a model control group was set up at the same time, with a capacity of 3mL per well. After 48 hours of treatment at 35°C, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. Data were collected using NIS-Elements D 3.20 advanced image processing software to analyze the fluorescence intensity (T) of human colon cancer cells. The statistical analysis results of this indicator were used to evaluate the efficacy of the sample in inhibiting tumor cell growth. The statistical processing results were expressed as mean ± SE. The calculation formula is as follows:

[0103]

[0104] SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.

[0105] Under the experimental conditions, the anti-tumor efficacy of the samples MTC was 125 μg / mL, as shown in Table 6; and all of them had the effect of inhibiting tumor growth, as shown in the results Figure 1 and Figure 2 .

[0106] (2) Experiment on the efficacy of inhibiting tumor cell metastasis:

[0107] Human colon cancer cells (HT-29) were labeled with CM-DiI and transplanted into the yolk sac of wild-type AB zebrafish at 2dpf by microinjection. About 200 cells were transplanted per tail to establish a zebrafish tumor transplantation model. The model zebrafish were cultured at 35℃ until 3dpf. At 3dpf, zebrafish with good consistency of transplanted tumor cells were selected under a microscope and randomly assigned to 6-well plates, with 30 tails per well. The samples (concentrations of 31.2, 62.5 and 125μg / mL) and the positive control 5-FU (concentrations of 65.0 and 260μg / mL) were given water-soluble, respectively. At the same time, a model control group was set up with a volume of 3mL per well. After 48h of treatment at 35℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The data were collected using NIS-Elements D 3.20 advanced image processing software to analyze the metastasis distance (S) of human colon cancer cells. The statistical analysis results of this indicator were used to evaluate the efficacy of the sample in inhibiting tumor cell metastasis. The statistical results were expressed as mean ± SE. The calculation formula is as follows:

[0108]

[0109] SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.

[0110] Under the experimental conditions, all groups of samples have the effect of inhibiting tumor metastasis. Figure 3 and Figure 4 .

[0111] (3) Test on promoting cell apoptosis:

[0112] Human colon cancer cells (HT-29) were transplanted into the yolk sac of 2dpf wild-type AB strain zebrafish by microinjection, with about 200 cells transplanted per tail to establish a zebrafish tumor transplantation model. The model zebrafish were cultured at 35°C until 3dpf. At 3dpf, zebrafish with good consistency of transplanted tumor cells were selected under a microscope and randomly assigned to 6-well plates, with 30 tails per well. The samples (concentrations of 31.2, 62.5 and 125μg / mL) and the positive control 5-FU (concentrations of 65.0 and 260μg / mL) were administered in water respectively, and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. After treatment at 35°C for 48 hours, each experimental group was stained with acridine orange in the dark for 15 minutes, washed three times with standard diluted water, and 10 zebrafish were randomly selected and photographed under a fluorescence microscope. The data were collected using NIS-Elements D 3.20 advanced image processing software to analyze the fluorescence intensity of apoptotic cells (A). The statistical analysis results of this indicator were used to evaluate the efficacy of the sample in promoting cell apoptosis. The statistical processing results were expressed as mean ± SE. The calculation formula is as follows:

[0113]

[0114] SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.

[0115] Under the experimental conditions, all samples in each group have the effect of promoting cell apoptosis. Figure 5 and Figure 6 .

[0116] (4) Angiogenesis inhibition efficacy test:

[0117] Human colon cancer cells (HT-29) were transplanted into the yolk sac of 2dpf transgenic vascular green fluorescent Fli-1 strain zebrafish by microinjection, with about 200 cells transplanted per tail to establish a zebrafish tumor transplantation model. Zebrafish with good consistency of transplanted tumor cells were selected under a microscope and randomly assigned to 6-well plates, with 30 tails per well. The samples (concentrations of 31.2, 62.5 and 125μg / mL) and the positive control 5-FU (concentrations of 65.0 and 260μg / mL) were given water-soluble, respectively. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. After 48h of treatment at 35℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The data were collected using NIS-Elements D 3.20 advanced image processing software to analyze the number of intestinal vascular sprouts (S). The statistical analysis results of this indicator were used to evaluate the efficacy of the sample in inhibiting angiogenesis. The statistical processing results are expressed as mean±SE. The calculation formula is as follows:

[0118]

[0119] SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.

[0120] Under the experimental conditions, all samples in each group have the effect of inhibiting angiogenesis. Figure 7 and Figure 8 .

[0121] (5) Anti-tumor mechanism research (gene) experiment:

[0122] Human colon cancer cells (HT-29) were transplanted into the yolk sac of 2dpf wild-type AB strain zebrafish by microinjection, with about 200 cells transplanted per tail to establish a zebrafish tumor transplantation model. The model zebrafish were cultured at 35℃ until 3dpf. At 3dpf, zebrafish with good consistency of transplanted tumor cells were selected under a microscope and randomly assigned to 6-well plates, with 30 tails per well. The samples were given water-soluble (concentrations of 31.2, 62.5 and 125μg / mL), positive control 5-FU (concentrations of 65.0 and 260μg / mL), and normal control group and model control group were set up at the same time. The volume of each well was 3mL, and three biological replicates were set up in parallel. After 48h of treatment at 35℃, the zebrafish samples of each group were collected, and the total RNA of each group of zebrafish was extracted using an RNA rapid extraction kit, and the total RNA concentration and purity were determined using a UV-visible spectrophotometer. 2.00 μg of total RNA from zebrafish samples was taken and 20.0 μL of cDNA was synthesized according to the instructions of the cDNA first-strand synthesis kit. The expression of β-actin, Bax, IFNG1, TNF-α and vegfaa genes was detected by q-PCR. β-actin was used as an internal reference for gene expression to calculate the relative RNA expression of Bax, IFNG1, TNF-α and vegfaa genes. The statistical results were expressed as mean ± SE. SPSS26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.

[0123] After the sample treatment, the zebrafish total RNA was extracted, and the RNA concentration and A260 / A280 ratio were determined by UV-visible spectrophotometer, as shown in Table 7; the A260 / A280 ratios were all between 1.8 and 2.2, indicating that the extracted zebrafish total RNA was of good quality and could be used for subsequent q-PCR experiments. The primer sequences are shown in Table 8.

[0124] Table 7 Total RNA concentration and A260 / A280 ratio (n=3)

[0125]

[0126]

[0127] Under the experimental conditions, each sample group and the sample and 5-FU combination group can upregulate the expression of Bax, IFNG1 and TNF-α genes, and downregulate the expression of vegfaa gene. Figure 9-12 .

[0128] The above results show that clam peptides can have a good anti-tumor effect and can be used in anti-tumor related drugs or products.

[0129] Experimental Example 3 Evaluation of the anti-tumor efficacy of clam peptide samples on inflammatory colorectal tumor model mice

[0130] SPF grade C57BL / 6 male mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. (5 weeks old, weighing 17-19 g).

[0131] After one week of adaptive feeding, the mice were divided into groups and the inflammatory colorectal tumor model was established using azoxymethane (AOM) / dextran sulfate sodium (DSS, relative molecular mass 36000-50000). Except for the blank group, a single intraperitoneal injection of AOM solution (10 mg / kg) was given, and 7 days later, a 2% DSS solution was given in drinking water for 7 consecutive days, after which DSS was stopped and normal drinking water was restored for 14 days. After this process was repeated for 3 cycles, the colorectal inflammatory tumor model was established, as shown in Table 9.

[0132] Table 9 Modeling process and grouping information

[0133]

[0134]

[0135] Weigh your body weight every 7 days, record and monitor changes in body weight. Fig.13 A. If there is death in the middle, record the time and number of deaths, calculate the survival cycle, and evaluate the disease activity of mice.

[0136] Colon detection indicators: colon length statistics are shown in Fig.13 Middle B: Colon tumor pathological section staining (H&E), observation of colon mucosal layer structure, folds, crypts and goblet cell numbers, etc., the results are shown in Fig.14 The expression of inflammatory factors (including IL-2, IL-10, IL-1β and TNF-α) in mouse serum was detected by ELISA kit (Wuhan Cloud-Clone Technology Co., Ltd.). The results are shown in Fig.15 , as well as the expression of lipopolysaccharide (LPS) and carcinoembryonic antigen (CEA). The results are shown in Fig.16 .

[0137] The expression of CD86, nitric oxide synthase (INOS), mannose receptor (CD206), and cyclooxygenase-2 (COX-2) in colon tissue was analyzed by immunohistochemistry. Fig.17 The expression of cell proliferation markers (Ki67) and proliferating cell nuclear antigen (PCNA) was analyzed by immunofluorescence. Fig.18 .

[0138] The obtained data were analyzed and processed using SPSS software. The results were analyzed by variance analysis and expressed as the mean ± standard deviation of the index. p<0.05 indicated a significant difference, and p<0.01 indicated an extremely significant difference. Compared with the model control group, *p<0.05, **p<0.01; compared with the blank group, #p<0.05, ##p<0.01.

[0139] Immunohistochemistry test method: CD86, INOS, CD206 and COX-2 were analyzed on paraffin sections of colon tissue. The sections were dewaxed, rehydrated, antigen repaired, washed with 5% BSA, and then reacted with the corresponding antibodies for 1 hour. Then, the slides were incubated with the corresponding secondary antibodies at 37°C for 1 hour and developed with DAB. After dehydration and transparency, the slides were scanned with a slide scanner.

[0140] Immunofluorescence assay method: Ki67 and PCNA analysis was performed on paraffin sections of colon tissue. The sections were dewaxed, rehydrated, antigen retrieved, washed with 5% BSA, and then reacted with antibodies for 1 hour. Next, the slides were incubated with the corresponding secondary antibodies at 37°C for 1 hour, stained with DAPI, and observed under a fluorescence microscope.

[0141] Observe the colon status and analyze Fig.13 The results showed that the representative photos of the colon showed that the colon of the control group was of moderate length, tough, and had uniform intestinal wall thickness, while the colon of the model group was shorter, less tough (easily broken), with thinner intestinal walls, and obvious lesions inside the colon. The symptoms of the two dose groups of clam peptide were alleviated, and the lesion tissue inside the colon was significantly reduced. In terms of effect, the high-dose group was better than the low-dose group.

[0142] Fig.14 The results showed that in the control group, the colon mucosal layer had a complete structure, rich wrinkles, long and dense intestinal glands, a large number of crypts, a large number of goblet cells, and no inflammation; in the model group, the intestinal wall was thinned, the colon mucosa was ulcerated, the wrinkles disappeared, most of the intestinal glands were necrotic, the crypts were greatly reduced, and the structure was destroyed. The number of goblet cells was severely reduced, and there was inflammatory infiltration. In the two dose groups of clam peptide, the degree of colon lesions was significantly improved, the intestinal gland necrosis was reduced, and the number of crypts and goblet cells increased. In terms of effect, the high-dose group was better than the low-dose group.

[0143] Fig.15The results showed that the IL-2 content in the model group was the lowest. After oral administration of clam peptides, the IL-2 content in the two dose groups increased significantly, and there was a significant difference compared with the model group (P<0.05). The low-dose and repeated groups had better effects than the high-dose group. The IL-10 content in the model group was the lowest. After oral administration of clam peptides, the IL-10 content in the two dose groups increased, and there was a significant difference compared with the model group (P<0.05). The high-dose group had the best effect. After oral administration of clam peptides, the IL-1β content in the two dose groups decreased significantly, and there was a significant difference compared with the model group (P<0.05). There was no significant difference between the dose groups. The expression of IFN-γ was the highest in the model group, and the expression was low in the blank group. The IFN-γ levels in the two dose groups were similar to those in the blank group, and there was a significant difference compared with the model group (p<0.05).

[0144] Carcinoembryonic antigen (CEA) is a specific marker for the early diagnosis of colon cancer and rectal cancer. Through a large amount of clinical practice, it was found that CEA values ​​can be elevated not only in gastrointestinal malignancies, but also in the serum of breast cancer, lung cancer and other malignant tumors.

[0145] Disruption of the intestinal microbiota increases LPS production in intestinal epithelial cells and leads to impaired intestinal barrier function and endotoxemia. Accumulating evidence suggests that LPS is involved in the tumorigenesis of colitis-associated CRC.

[0146] Fig.16 The test results showed that the content of CEA in serum showed that CEA was expressed in large quantities in the model group, and after oral administration of clam peptide, the expression of CEA in the two dose groups was significantly reduced, and there was a significant difference compared with the model group (p<0.05), among which the high dose group had the best effect; the results of LPS in serum showed that after oral administration of clam peptide, the content of LPS in the two dose groups was significantly reduced, and there was a significant difference compared with the model group (p<0.05), among which the high dose group had the best effect.

[0147] Fig.17 The results of immunohistochemical analysis showed that the expression of CD86 and iNOS (M1 markers) in the sample group was significantly higher than that in the model group and the blank group, the expression of CD206 (M2 marker) was significantly lower than that in the blank and model groups, and the expression of cyclooxygenase-2 (COX-2) was significantly reduced.

[0148] Fig.18 The results of immunofluorescence analysis showed that the expression levels of Ki67 and PCNA proteins in the sample groups were significantly reduced, and the high-dose group was more obvious than the low-dose group.

[0149] The above results show that clam peptides effectively alleviate the symptoms of colorectal lesions, release numerous anti-tumor factors, and effectively inhibit the spread and growth of colorectal tumors, indicating that clam peptides have direct anti-tumor activity. At the same time, they can also play an anti-tumor role by regulating immune cells. They can be used in anti-tumor treatment and immune-assisted anti-tumor related drugs or products.

[0150] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A method for preparing an anti-tumor clam peptide, characterized in that: The specific steps are as follows: (1) The whole meat of Manila clam is used as raw material, washed and homogenized with pure water to obtain a clam meat slurry with a ratio of raw material to pure water of 1:2-3, the pH value thereof is adjusted to 7.8-8.5, the enzymatic hydrolysis temperature is set to 37-38° C., 0.03%-0.05% of trypsin by weight of the raw material is added, and after enzymatic hydrolysis for 3-5 hours, the enzyme is inactivated to obtain an enzymatic hydrolyzate; the enzymatic activity of the trypsin is 2500U; (2) centrifuging the enzymatic hydrolysate obtained in step (1), discarding the precipitate, filtering the supernatant through a 10 μm microfiltration membrane-50,000 Da ultrafiltration membrane-400 Da nanofiltration membrane, and intercepting the enzymatic hydrolysate with a molecular weight between 400 Da and 50,000 Da; spray drying to obtain clam peptides; the purity of the clam peptides reaches 70% or more, calculated by polypeptide content; the proportion of peptides with a relative molecular mass of less than 5,000 Da in the clam peptides reaches 97% or more.

2. The method for preparing an anti-tumor clam peptide according to claim 1, characterized in that: The enzyme inactivation treatment in step (1) is performed at 80-100° C. for 15-20 min.

3. The method for preparing an anti-tumor clam peptide according to claim 1, characterized in that: The centrifugation in step (2) is performed at 5000 rpm for 20 min.

4. The clam peptide prepared by the preparation method according to any one of claims 1 to 3.

5. Use of the clam peptide according to claim 4 in the preparation of anti-tumor drugs.

6. The use according to claim 5, characterized in that: The tumor is colorectal cancer.

7. Use of the clam peptide according to claim 4 in the preparation of immunomodulatory drugs.

8. The use according to any one of claims 5 to 7, characterized in that: The medicine is in the form of oral, injectable or external use.